Connor, Clark & Lunn Investment Management (CC&L)’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-576,354	Closed	-$1.31M	–	1696
2024 Q2	$1.31M	Buy	576,354 +162,775	+39%	+$622K	0.01%	780
2024 Q1	$1.79M	Buy	413,579 +221,469	+115%	+$772K	0.01%	705
2023 Q4	$586K	Sell	192,110 -12,090	-6%	-$22.7K	﹤0.01%	999
2023 Q3	$294K	Buy	204,200 +82,879	+68%	+$160K	﹤0.01%	1149
2023 Q2	$302K	Buy	121,321 +104,808	+635%	+$286K	﹤0.01%	1104
2023 Q1	$44.3K	Buy	+16,513	New	+$79.3K	﹤0.01%	1195
2022 Q4	–	Sell	-90,139	Closed	-$1.13M	–	1469
2022 Q3	$1.13M	Buy	90,139 +50,481	+127%	+$577K	0.01%	627
2022 Q2	$196K	Buy	+39,658	New	+$220K	﹤0.01%	938
2021 Q4	–	Sell	-26,211	Closed	-$352K	–	1236
2021 Q3	$352K	Buy	+26,211	New	+$427K	﹤0.01%	840
2021 Q1	–	Sell	-23,330	Closed	-$420K	–	1118
2020 Q4	$420K	Buy	+23,330	New	+$349K	﹤0.01%	745

Connor, Clark & Lunn Investment Management (CC&L)'s GTHX Position: Q3 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 576,354 shares — an estimated $1.31M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GTHX in Q4 2020 and held it in 10 quarters. The position peaked at $1.79M in Q1 2024. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 576,354 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.31M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s G1 Therapeutics, Inc. Common Stock position peaked at $1.79M in Q1 2024.
0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2024, filed 8 Nov 2024.